Nuvalent, Inc. 8-K

What Happened

• Nuvalent, Inc. announced the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. A total of 71,190,894 shares of Class A common stock were present or represented by proxy, about 96.80% of outstanding Class A shares as of the April 20, 2026 record date.
• The board’s Class II director nominees were elected, the company’s executive compensation was approved on an advisory basis, and KPMG LLP was ratified as the independent registered public accounting firm for fiscal 2026. The company’s definitive proxy was filed April 28, 2026.

Key Details

• Shares present/represented: 71,190,894 (≈96.80% of Class A as of Apr 20, 2026).
• Director elections (three-year terms expiring 2029):
  • Michael L. Meyers, M.D., Ph.D.: For 57,592,636; Withheld 13,110,466; Broker non-votes 487,792.
  • Ron Squarer: For 70,612,828; Withheld 90,274; Broker non-votes 487,792.
• Advisory vote on executive compensation (say-on-pay): For 68,898,711; Against 1,786,465; Abstain 17,926; Broker non-votes 487,792.
• Ratification of auditor (KPMG LLP) for fiscal 2026: For 71,172,889; Against 858; Abstain 17,147; no broker non-votes reported.

Why It Matters

• The outcomes confirm the company’s board composition and governance path for the next three years and show strong investor turnout and support for company proposals.
• The advisory approval of executive compensation (say-on-pay) signals broad shareholder support for management pay practices, though the withheld votes on one director (Dr. Meyers) indicate some investor dissent to monitor.
• Ratification of KPMG as auditor affects who will audit Nuvalent’s 2026 financial statements, an important factor for financial reporting and investor confidence.